Ad is loading...
INCY
Price
$75.87
Change
-$1.86 (-2.39%)
Updated
Nov 15 closing price
88 days until earnings call
JAZZ
Price
$121.65
Change
-$2.62 (-2.11%)
Updated
Nov 15 closing price
107 days until earnings call
Ad is loading...

INCY vs JAZZ

Header iconINCY vs JAZZ Comparison
Open Charts INCY vs JAZZBanner chart's image
Incyte
Price$75.87
Change-$1.86 (-2.39%)
Volume$3.84M
CapitalizationN/A
Jazz Pharmaceuticals
Price$121.65
Change-$2.62 (-2.11%)
Volume$718.17K
CapitalizationN/A
INCY vs JAZZ Comparison Chart
Loading...
INCY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
JAZZ
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
INCY vs. JAZZ commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Sell and JAZZ is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (INCY: $75.87 vs. JAZZ: $121.65)
Brand notoriety: INCY: Notable vs. JAZZ: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INCY: 198% vs. JAZZ: 115%
Market capitalization -- INCY: $14.62B vs. JAZZ: $7.35B
INCY [@Biotechnology] is valued at $14.62B. JAZZ’s [@Biotechnology] market capitalization is $7.35B. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCY’s FA Score shows that 2 FA rating(s) are green whileJAZZ’s FA Score has 0 green FA rating(s).

  • INCY’s FA Score: 2 green, 3 red.
  • JAZZ’s FA Score: 0 green, 5 red.
According to our system of comparison, INCY is a better buy in the long-term than JAZZ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCY’s TA Score shows that 3 TA indicator(s) are bullish while JAZZ’s TA Score has 6 bullish TA indicator(s).

  • INCY’s TA Score: 3 bullish, 6 bearish.
  • JAZZ’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, JAZZ is a better buy in the short-term than INCY.

Price Growth

INCY (@Biotechnology) experienced а -9.01% price change this week, while JAZZ (@Biotechnology) price change was -1.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

INCY is expected to report earnings on Feb 13, 2025.

JAZZ is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INCY($14.6B) has a higher market cap than JAZZ($7.35B). INCY has higher P/E ratio than JAZZ: INCY (843.00) vs JAZZ (17.23). INCY YTD gains are higher at: 20.831 vs. JAZZ (-1.098). JAZZ has higher annual earnings (EBITDA): 1.22B vs. INCY (365M). JAZZ has more cash in the bank: 1.98B vs. INCY (1.78B). INCY has less debt than JAZZ: INCY (36.5M) vs JAZZ (5.79B). INCY (4.08B) and JAZZ (3.91B) have equivalent revenues.
INCYJAZZINCY / JAZZ
Capitalization14.6B7.35B199%
EBITDA365M1.22B30%
Gain YTD20.831-1.098-1,898%
P/E Ratio843.0017.234,892%
Revenue4.08B3.91B104%
Total Cash1.78B1.98B90%
Total Debt36.5M5.79B1%
FUNDAMENTALS RATINGS
INCY vs JAZZ: Fundamental Ratings
INCY
JAZZ
OUTLOOK RATING
1..100
9232
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
62
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8664
PRICE GROWTH RATING
1..100
948
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
9585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JAZZ's Valuation (62) in the Pharmaceuticals Other industry is somewhat better than the same rating for INCY (97) in the Biotechnology industry. This means that JAZZ’s stock grew somewhat faster than INCY’s over the last 12 months.

JAZZ's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as INCY (100) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to INCY’s over the last 12 months.

JAZZ's SMR Rating (64) in the Pharmaceuticals Other industry is in the same range as INCY (86) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to INCY’s over the last 12 months.

INCY's Price Growth Rating (9) in the Biotechnology industry is somewhat better than the same rating for JAZZ (48) in the Pharmaceuticals Other industry. This means that INCY’s stock grew somewhat faster than JAZZ’s over the last 12 months.

INCY's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for JAZZ (100) in the Pharmaceuticals Other industry. This means that INCY’s stock grew significantly faster than JAZZ’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCYJAZZ
RSI
ODDS (%)
Bearish Trend 3 days ago
64%
Bearish Trend 3 days ago
64%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
59%
Bearish Trend 3 days ago
67%
Momentum
ODDS (%)
Bearish Trend 3 days ago
62%
Bullish Trend 3 days ago
61%
MACD
ODDS (%)
Bearish Trend 3 days ago
71%
Bullish Trend 3 days ago
63%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
66%
Bearish Trend 3 days ago
61%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
59%
Bullish Trend 3 days ago
67%
Advances
ODDS (%)
Bullish Trend 10 days ago
61%
Bullish Trend 6 days ago
63%
Declines
ODDS (%)
Bearish Trend 3 days ago
65%
Bearish Trend 3 days ago
60%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
65%
Bearish Trend 3 days ago
69%
Aroon
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 3 days ago
68%
View a ticker or compare two or three
Ad is loading...
INCY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
JAZZ
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KTEC13.310.09
+0.68%
KraneShares Hang Seng TECH ETF
SDVY38.09-0.21
-0.55%
First Trust SMID Cp Rising Div Achv ETF
ISMD38.71-0.29
-0.74%
Inspire Small/Mid Cap ETF
PRAY29.85-0.40
-1.31%
FIS Christian Stock ETF
ROM67.96-3.57
-4.99%
ProShares Ultra Technology

INCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCY has been loosely correlated with AXON. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCY
1D Price
Change %
INCY100%
-2.39%
AXON - INCY
39%
Loosely correlated
-0.86%
JAZZ - INCY
37%
Loosely correlated
-2.11%
INVA - INCY
36%
Loosely correlated
-1.77%
UTHR - INCY
36%
Loosely correlated
-5.96%
SRPT - INCY
33%
Poorly correlated
-4.19%
More